In the Boardroom
Refine Search
Pharmaceutical
US-based clinical biopharmaceutical company Mast Therapeutics has named Edwin Parsley, has joined the company as its chief medical officer and senior vice president. 2 October 2014
Pharmaceutical
US pain therapeutic specialists Relmada Therapeutics has appointed Julie Chen as its Director of Finance and Operations. 2 October 2014
Pharmaceutical
USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal cannabinoid treatments, has named two leading industry veterans to lead the company. 2 October 2014
Pharmaceutical
Privately-held gastrointestinal company Ritter Pharmaceuticals has appointed Michael Step as chief executive. 1 October 2014
Biotechnology
Cancer-focused genetic testing service provider NeoGenomics has appointed Robert Shovlin as chief operating officer. 30 September 2014
Biotechnology
Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief executive on an interim basis, following the departure of Torbjörn Bjerke from the position. 30 September 2014
Pharmaceutical
Oncology drug development company focused on antibody drug conjugates targeting major cancers, ADC Therapeutics, has expanded its team significantly as the company’s first antibody drug conjugates enter clinical development. 30 September 2014
Pharmaceutical
UK respiratory specialist Verona Pharma has appointed Biresh Roy as chief financial officer and member of the board of directors, taking over from Richard Bungay. 30 September 2014
Pharmaceutical
Israeli pharma company Protalix BioTherapeutics has appointed Moshe Manor as its new president and chief executive, effective from November 2. 29 September 2014
Pharmaceutical
UK pharma giant GlaxoSmithKline this morning confirmed recent rumors, saying that Sir Philip Hampton will join the company’s board as non-executive director from January 1, 2015, and will become deputy chairman with effect from April 1, 2015. 25 September 2014
Biotechnology
Inflammation, oncology and biodefense biopharma company Soligenix has announced the appointment of Rasappa Arumugham as vice president of biopharmaceutical development. 23 September 2014
Pharmaceutical
UK-based Avillion LLP, a co-developer of late-stage pharmaceutical assets, has named Jarrod Longcor as Chief Business Officer. 23 September 2014
Pharmaceutical
Swiss-based iron deficiency specialist Vifor Pharma has appointed Dario Eklund as head of international business operations, and Abdul Mullick as head of global marketing, at its headquarters in Zurich. 19 September 2014
Pharmaceutical
Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations, as part of an ongoing drive to deliver a more flexible model that unlocks cost efficiencies and alleviates some aspects of risk associated with drug development. Recruiting talent is one such element. However, pharma companies should be wary of saving on recruitment at the risk of missing out on the best candidates, particularly when it comes to senior staff. Director of Interims of RSA, Dafydd Wright explains. 19 September 2014
Pharmaceutical
The board of partners of Germany’s Merck KGaA has promoted Stefan Oschmann to the position of deputy chief executive and Vice Chairman of the Executive Board. 18 September 2014
Pharmaceutical
USA-based PTC Therapeutics is to expand its global presence by adding key executives to leadership positions in the global commercial team and establishing its international headquarters in Dublin, Ireland. 17 September 2014
Biotechnology
Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins as chief executive, who succeeds interim chief executive Thomas Beck. 17 September 2014
Pharmaceutical
Dutch biopharma company specializing in brain diseases, to-BBB, has appointed Anders Harfstrand as chief executive. 15 September 2014
Pharmaceutical
Oliver Siegel has been appointed as chief operating officer at Austrian vaccine specialist AFFiRiS AG, where he will take responsibility for business development, finance and administration. 9 September 2014
Pharmaceutical
Swedish drug developer Karolinska Development has appointed Bruno Lucidi as chief executive of the wholly-owned subsidiary KDev Oncology, and portfolio companies Aprea and Akinion Pharmaceuticals. 8 September 2014
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Pharmaceutical
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
French cancer vaccine focused biotech Oncovita has appointed Dr Stéphane Altaba as its new chief executive (CEO). 9 October 2024
Biotechnology
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Biotechnology
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Pharmaceutical
US pharma giant Pfizer (NYSE: PFE) has announced that John McGinley has been appointed UK managing director and country president. 7 October 2024
Pharmaceutical
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze